PTGX Protagonist Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PTGX

Price (delayed)

$138.7

Market cap

$8.98B

P/E Ratio

114.63

Dividend/share

N/A

EPS

$1.21

Enterprise value

$8.56B

?
Relative Growth: Rel. Growth: 91
Relative Strength: Rel. Strength: 91
Relative Valuation: Rel. Valuation: 12
Relative Profitability: Rel. Profitability: 95

Protagonist Therapeutics is a late-stage development biopharmaceutical company focused on peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with ...

Highlights
The net income has surged by 172% since the previous quarter and by 59% year-on-year
Protagonist Therapeutics's EPS has surged by 167% QoQ and by 42% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.protagonist-inc.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of PTGX

PTGX stock price

How has the Protagonist Therapeutics stock price performed over time
Intraday
-4.39%
1 week
-2.9%
1 month
-10.12%
1 year
113.19%
YTD
58.8%
QTD
13.15%

Financial performance

How have Protagonist Therapeutics's revenue and profit performed over time
Revenue
$281.99M
Gross profit
$281.99M
Operating income
$58.34M
Net income
$82.91M
Gross margin
100%
Net margin
29.4%
The net income has surged by 172% since the previous quarter and by 59% year-on-year
PTGX's operating income has surged by 143% year-on-year and by 141% since the previous quarter
The net margin has surged by 119% since the previous quarter and by 18% year-on-year
The operating margin has soared by 111% from the previous quarter and by 80% YoY

Price vs fundamentals

How does PTGX's price correlate with its fundamentals

Growth

What is Protagonist Therapeutics's growth rate over time

Valuation

What is Protagonist Therapeutics stock price valuation
PTGX P/E details
P/E
114.63
P/B
10.6
P/S
32.43
EV/EBIT
101.55
EV/EBITDA
98.2
EV/Sales
30.37
Protagonist Therapeutics's EPS has surged by 167% QoQ and by 42% YoY
The P/B is 136% more than the 5-year quarterly average of 4.7 and 27% more than the last 4 quarters average of 8.7
The equity has grown by 28% from the previous quarter and by 26% YoY
The stock's price to sales (P/S) is 67% less than its 5-year quarterly average of 103.0 and 48% less than its last 4 quarters average of 65.6
Protagonist Therapeutics's revenue has increased by 35% YoY

Efficiency

How efficient is Protagonist Therapeutics business performance
The ROIC has soared by 176% from the previous quarter and by 71% YoY
PTGX's ROA has soared by 168% since the previous quarter and by 51% year-on-year
The company's return on equity has surged by 167% QoQ and by 48% YoY
Protagonist Therapeutics's return on sales has surged by 119% QoQ and by 16% YoY

Dividends

What is PTGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PTGX.

Financial health

How did Protagonist Therapeutics financials performed over time
The quick ratio has grown by 33% YoY and by 23% from the previous quarter
The current ratio is up by 28% year-on-year and by 22% since the previous quarter
The debt is 99% smaller than the equity
The debt to equity has plunged by 50% YoY
The equity has grown by 28% from the previous quarter and by 26% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.